Results of clinical effectiveness of conventional versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial.
Scott A KoepsellMoritz StollaRebecca L SedjoJeffrey L CarsonCharles Michael KnudsonRichard CookRoss M FasanoSamantha G NgamsuntikulClaudia S CohnJed GorlinMeghan DelaneySherrill SlichterPaul NessJeffrey McCulloughPublished in: Transfusion (2024)
This study did not support that MIRASOL was non-inferior compared to conventional platelets using the novel endpoint number of days with ≥Grade 2 bleeding in MIRASOL when compared to CONTROL.